Cytodigm’s business model is built on collaboration. We develop therapeutics to clinical proof of concept for our technology platforms, leveraging their value through partnerships with other biopharmaceutical companies. This collaborative approach allows us to out-license the technology for different disease indications, ensuring a wider reach and impact.
Cytodigm’s delivery platforms have proven their success by packaging a variety of therapeutic payloads and delivering them to different disease sites. Zetafinity® polymeric nanoparticles, for instance, are most suitable for delivering small molecules, peptides, and proteins to immune cells to treat autoimmune diseases and cancer. This technology platform has been out-licensed for disease indications outside of oncology, and numerous programs of our licensee and sublicensees are in late-stage clinical trials, a testament to the effectiveness of this delivery platform.
Cytofinity™ lipid nanoparticle (LNP) is a tool for active targeting without the use of antibody conjugation. It transports siRNA, ASO, mRNA, DNA, gene-editing constructs, circular RNA, and other nucleic acid-based therapeutics to different cells and tissues. Cytodigm is open to collaborating with other biopharmaceutical companies to utilize Cytofinity™ LNPs to enhance the therapeutic impact of in vivo cell, gene, and immune therapy for patients.
Cytodigm’s technologies are covered by its extensive intellectual property portfolio and are potentially available for licensing as part of a collaboration. For any collaboration opportunities, please contact info@cytodigm.com.
